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Abstract
Background: The amino terminal half of the cellular prion protein PrPc is implicated in both the
binding of copper ions and the conformational changes that lead to disease but has no defined
structure. However, as some structure is likely to exist we have investigated the use of an
established protein refolding technology, fusion to green fluorescence protein (GFP), as a method
to examine the refolding of the amino terminal domain of mouse prion protein.
Results: Fusion proteins of PrPc and GFP were expressed at high level in E.coli and could be purified
to near homogeneity as insoluble inclusion bodies. Following denaturation, proteins were diluted
into a refolding buffer whereupon GFP fluorescence recovered with time. Using several truncations
of PrPc the rate of refolding was shown to depend on the prion sequence expressed. In a variation
of the format, direct observation in E.coli, mutations introduced randomly in the PrPc protein
sequence that affected folding could be selected directly by recovery of GFP fluorescence.
Conclusion: Use of GFP as a measure of refolding of PrPc fusion proteins in vitro and in vivo proved
informative. Refolding in vitro suggested a local structure within the amino terminal domain while
direct selection via fluorescence showed that as little as one amino acid change could significantly
alter folding. These assay formats, not previously used to study PrP folding, may be generally useful
for investigating PrPc structure and PrPc-ligand interaction.
Background
The cellular prion protein PrPc is a glycosylinositol phos-
pholipid (GPI) anchored glycoprotein present on neuro-
nal and other cells [1,2] with a demonstrable ability to
bind and transport copper ions [3-6]. The protein is essen-
tial for susceptibility to the Transmissible Spongiform
Encephalopathies (TSEs) where the accumulation of a dis-
ease associated conformational variant, PrPSc, is depend-
ent on the presence of the cellular PrPc  isoform (for
reviews [7-9]). A role for prion protein in copper metabo-
lism may be linked to cell resistance to oxidative stress
and, thereby, to pathology [10-16]. The C-terminal
domain of mouse PrPc, whose structure has been deter-
mined by NMR, has three α-helices and a short section of
antiparallel β-sheet [17]. It folds quickly in vitro to a stable
structure largely unaffected by amino acid substitution
[18,19]. By contrast, the N-terminal domain of PrPc is flex-
ibly disordered in the full-length molecule [20,21]. This
region encodes the octarepeat motifs (residues 23–90)
responsible for low affinity copper binding [3,4,22-24]
and the central hydrophobic region of PrPc observed to be
toxic to cells in culture [25], that also binds copper
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[6,15,26] and is involved in the conversion of PrPc to PrPSc
[27-29]. Prion diseases have been proposed to be essen-
tially diseases of protein folding [30-32] in which mis-
folded PrPc, triggered by the presence of PrPSc, forms
aggregates associated with toxicity. Equally, misfolded
PrPc could be linked to disease through failure to fulfil its
normal function, possibly in copper transport [6,33,34].
In keeping with these models, antibodies or tagged PrPc
that compete for prion protein interaction prevent the
accumulation of PrPSc [35,36] and subsequent pathology
[37,38]. Pathology could also result from aberrant or
amplified signalling, leading to apoptosis, a situation
mimicked by the binding of antibodies that cross link cell
surface PrPc  [39]. Interestingly, antibodies that cause
apoptosis map to the unstructured domain (residues 95–
105) while those binding to the structured C-terminal half
of PrPc are not active [39]. Thus, methods that address
prion protein folding may help describe the exact link
between folding and the various properties ascribed to the
PrPc  molecule. We have investigated a methodology
developed originally to improve the expression of pro-
teins for structural studies [40-42] to report on prion pro-
tein folding. Using constructs with endpoints reported
previously to alter expression levels [43] we show that
PrPc-GFP fusions protein can be refolded in vitro and that
folding is related to the sequence of the PrPc expressed. In
addition, mutations that directly affect folding can be
selected from a random expression libraries based of the
recovery of GFP fluorescence. The use of a co-folding part-
ner thus offers an indirect measure of prion protein fold-
ing both in vivo and in vitro.
Results
Establishment of PrPc-GFP refolding in vitro
The chromophore of GFP is made up of the tripeptide
sequence Ser-Tyr-Gly that cyclizes in the folded form of
the protein [44,45]. Denaturation and reduction abolish
fluorescence but it can be recovered by dilution into a
refolding buffer where the rate of fluorescence re-acquisi-
tion parallels protein folding [46,47]. GFP extended at the
N-terminus can also be refolded with a similar recovery of
fluorescence [40,41]. To assess this technology as a meas-
ure of PrPc folding, we expressed GFP appended at the N-
terminus with the complete mature prion protein (resi-
dues 23–231) and a short fragment of PrPc, residues 76–
156, as a control for the effect of size of the amino termi-
nal extension on refolding (Fig 1A). Expression of the PrPc
23–231-GFP and PrPc 
76–156-GFP fusion protein in E.coli led
to the accumulation of non-fluorescent insoluble inclu-
sion bodies that were purified to ~90% (Fig 1B) and then
denatured before dilution into refolding buffer. GFP fluo-
rescence (510 nm) rose with time to a maximum refold-
ing level of ~6 fold for PrPc 
23–231-GFP and ~25 fold for
PrPc 
76–156-GFP over background within 3 hrs under the
conditions of the experiment (Fig 1C). Ranging experi-
Establishment of the Prp-GFP refolding assay Figure 1
Establishment of the Prp-GFP refolding assay. A. Fragments 
of the mouse prnp a allele whose structure is shown were 
amplified by PCR and positioned at the N terminus of GFP in 
a E.coli expression vector under transcriptional control of the 
T7 promoter. B. Purified PrP-GFP fusion proteins were ana-
lysed by 10% SDS-PAGE before (lanes 1 & 2) and after (lanes 
3 & 4) the refolding reaction. The lanes are: M-Molecular 
weight markers as shown; 1&3-PrP23–231-GFP; 2&4-PrP76–156-
GFP. The lower staining intensity of the refolded samples is 
due to dilution in the refolding buffer. C. Recovery of fluo-
rescence with time following dilution of the solublised PrP-
GFP fusion proteins into refolding buffer. In this experiment 
the increase in fluorescence units was 6 fold () and 27 fold 
(●) for PrP23–231-GFP and PrP76–156-GFP respectively. Assays 
were done in duplicate and the average fluorescent units 
plotted against time.Virology Journal 2006, 3:59 http://www.virologyj.com/content/3/1/59
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ments showed optimal refolding to occur at >pH8 and at
21°C (not shown). We conclude from this data that 1)
PrPc-GFP fusion proteins can refold in vitro to regenerate
the GFP chromophore and 2) the level of refolding is
related to the PrPc sequence fused to GFP as alteration of
the fragment size altered the rate of fluorescence recovery.
The observed fluorescence was directly attributable to
refolding of PrPc-GFP as re-examination of the fusion pro-
teins after the refolding assay showed full length protein
in solution with no evidence of breakdown to release free
GFP (Fig. 1B). As PrPc binds both copper [3,4,26,48,49]
and RNA [50-52] the effect of both of these ligands on the
refolding reaction of full length prion protein present in
construct PrPc 
23–231-GFP was assessed. However, neither
addition of copper (100 nM) nor RNA, prepared as
described [51], significantly altered the rate of fluores-
cence recovery for the full length prion protein, which
remained slow when compared to the shorter variant (see
Additional file 1).
Use of GFP refolding to assess the role of the extreme N 
terminus
Previous expression of PrPc-GFP fusion proteins within
eukaryotic cells indicated a marked effect of the extreme
N-terminal basic residues 23–28 on prion protein
processing [53,54] and further studies have suggested an
interaction between the extreme amino terminus and the
C terminal folded domain [43] extending an earlier anti-
body binding study [55]. In order to assess directly if the
N terminal sequence affects folding per se, amino terminal
truncations were made in which PrPc residues 23–156,
29–156, 23–169 and 29–169 (see 1) were appended to
the N terminus of GFP and the fusion proteins purified as
an insoluble fraction prior to dilution into the refolding
reaction (Fig. 2A). When equimolar amounts of each
fusion protein were subjected to the refolding assay, the
rates of fluorescence reacquisition were found to vary con-
siderably (Fig. 2B). The presence of residues 23–28 at the
extreme N-terminus of PrPc severely limited refolding in
the context of a fragment truncated at residue 156 with
overall refolding little better than the complete 23–231
PrPc sequence despite being a considerably shorter frag-
ment (cf Fig. 1). Deletion of residues 23–28 (construct
PrPc 
29–156-GFP) enhanced fluorescence recovery ~4 fold
when compared to PrPc 
23–156-GFP (Fig. 2B). However, a
fragment starting at residue 23 but with an extended C-ter-
minal truncation point at residue 169 (PrPc 
23–169-GFP),
refolded far more efficiently than PrPc 
23–156-GFP (Fig. 2B)
and deletion of the amino terminal 6 residues in PrPc 
29–
169-GFP failed to improve the level of fluorescence
observed. Fluorescence recovery was associated with
equivalent quantities of soluble full-length fusion protein
as no free GFP was apparent when the refolded samples
were analysed by SDS-PAGE after removal from the
refolding reaction (Fig. 2A). Thus, recovery of fluores-
cence by PrPc-GFP fusion proteins in vitro following dena-
turation and renaturation measures a direct role for
residues 23–28 and 156–169 in folding and mirrors the
expression patterns observed for prion protein fragments
of the same endpoints in vivo [43].
Use of GFP for direct selection of folding variants
That GFP fluorescence recovered in vitro reflected proper-
ties measured in eukaryotic cells suggested that PrPc-GFP
fusions retained a degree of physiological significance. We
sought therefore to use fluorescence for the direct selec-
tion of prion mutants with altered folding properties. To
do this we used the plasmid encoding PrPc 
23–231-GFP as
template for error prone PCR based mutagenesis [56] of
the PrPc sequence followed by substitution of the degen-
erate amplified material for the wild type sequence in
order to generate a library of random PrPc mutations fused
to GFP (see 1). Nucleotide sequencing of several library
members picked at random showed a variety of sequence
changes causing premature stop codons as well as single
or multiple amino acid changes within the PrPc coding
region (not shown). To select altered folding variants the
library was plated at high density, replicated to agar plates
containing IPTG and colonies were screened for fluores-
cence following irradiation with ultraviolet light. The
overall number of fluorescent colonies was low and after
eradication of false positives three mutants (M17, M22
and M25), which showed particularly strong fluorescence,
(Fig. 3) were isolated and characterised further. As a recov-
ery in fluorescence could indicate a change in folding and
solubility bacterial cultures of the parental construct and
each fluorescent variant were induced, harvested and
lysed and the level of PrPc-GFP fusion protein present in
the soluble and insoluble fractions was assessed by west-
ern blot using the PrPc  monoclonal antibody 6H4
(epitope 144–152). As noted the parental sequence was
wholly insoluble but significant amounts of the fusion
protein from variants M22 and M25 and approximately
50% of the protein from mutant M17 were found in the
supernatant fraction (Fig. 4). One variant (M22) showed
substantial proteolysis leading to loss of full length anti-
body reactive material in the supernatant fraction, a char-
acteristic of soluble PrPc expression in E.coli [57]. DNA
sequencing of each variant revealed that M22 and M25
each had two amino acid changes, E152V+N48S and
Y149H+G228E respectively while variant M17 showed
only a single amino acid change at H84Q (Figure 5). Thus,
changes of as little as one or two amino acids throughout
the PrPc polypeptide chain can cause significant alteration
in protein folding. None of the mutations selected by this
procedure occurred in the prion hydrophobic sequence
(amino acids 111–133) rather, as suggested, change of
charge was the predominant feature observed [58].Virology Journal 2006, 3:59 http://www.virologyj.com/content/3/1/59
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Discussion
The use of protein fusions as reporters of protein folding
and solubility has emerged rapidly and includes use of
chloramphenicol acetyltransferase (CAT) [59], β-galactos-
idase [60,61] and secretion by defined bacterial transloca-
tion systems [62]. The most well defined system however
has been fusion to the N terminus of GFP [40,42]
although fusions within the loops of the folded structure
have also been reported [63]. The requirement for
increased folding and solubility has been largely driven by
the production of proteins for structural studies [64] but
studies with known misfolding proteins such as Alzhe-
imer's amyloid beta peptide have shown that they can be
equally applied to the study of folding per se [60,62]. Here
we showed that fusion of GFP to the C-terminus of the
mouse prion protein or fragments thereof can provide a
measure of the role of prion sequence in folding in vitro
and that direct selection of fluorescence in vivo results in
PrPc-GFP fusion proteins with altered proprieties of solu-
bility. Refolding of PrPc-GFP fusions was found to be
robust and not to result in degradation but marked varia-
tion in efficiency was noted when the refolding of individ-
ual fragments of PrPc was investigated. In particular, the
presence or not of residues 23–28 (KKRPKP), highly con-
served in prion sequences [65], substantially affected
refolding in vitro and mirrored their affect on PrPc-GFP
fusion protein expression in vivo [43]. The diverse biolog-
ical properties of this region, including binding of prion
protein to charged molecules such as Heparin and GAGs
[66-69], suramin [70] and cellular routing [53,54] would
be consistent with a role on the overall structure of the
prion protein. Indeed, restricting movement by N-termi-
nal tethering of PrPc to the cell surface abrogates the only
known function of the protein, cellular resistance to oxi-
dative stress [71]. Previous antibody binding studies have
suggested that the prion N-terminus may contact the car-
boxyl domain [72] and we have previously suggested this
interaction may occur between the basic amino terminus
and the acidic patch in helix-1 (143DWED146) [43]. Matsu-
naga et al., using an N-terminally truncated PrPc molecule,
previously proposed a model in which the free N-terminal
amine of PrPc residue 90 (the truncation point) interacted
with the acidic charge cluster in helix-1 following the
observation that cryptic epitopes for monoclonal anti-
Refolding of PrPc-GFP fusion proteins containing fragments from the prion amino terminal domain Figure 2
Refolding of PrPc-GFP fusion proteins containing fragments from the prion amino terminal domain. A. 10% SDS-PAGE analysis 
of purified PrP-GFP fusion proteins encoding fragments from the N-terminus before (lanes 1–4) and after (5–8) refolding. 
Lanes 1 & 5, PrPc 
23–156-GFP; lanes 2&6, PrPc 
29–156-GFP; lanes 3&7, PrPc 
23–169-GFP; lanes 4&8, PrPc 
29–169-GFP. B. In vitro refold-
ing kinetics of purified recombinant PrP-GFP fusion proteins; PrPc 
23–156-GFP (); PrPc 
29–156-GFP (●); PrPc 
23–169-GFP(■) and 
PrPc 
29–169-GFP(▲). Assays were done in duplicate and the average fluorescent units plotted against time. Fluorescence units 
are as recorded by the plate reader. The lower staining intensity of the refolded samples is due to dilution in the refolding 
buffer.Virology Journal 2006, 3:59 http://www.virologyj.com/content/3/1/59
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body 3F4 within the N-terminus are revealed by titration
of acidic residues around Glu 152 [55]. The GFP fluores-
cence recovery assay described here supports this model
but suggests it is residues 23–28 that have a direct role in
folding, consistent with binding to the carboxyl domain
described elsewhere [43]. While various properties have
been ascribed to this short section of charged residues
[43,53,54,67,68,70,73] use of refolding in vitro indicates
for the first time that these observations could be the
result of a role in the overall folding of the molecule.
A corollary of prion sequence identity affecting refolding
in vitro is that direct selection of fluorescence from the
non-fluorescent PrPc 
23–231-GFP should result in altered
solubility. To assess this we carried out forced evolution of
the PrPc sequence and used GFP to screen for a fluorescent
outcome. Model experiments have suggested that as little
a change as one amino acid can have a profound effect on
the physiochemical properties of complete proteins such
as α-synuclein but the effect of mutations associated with
PrPc has been only tested on isolated peptides [74] mak-
ing the same conclusion for the complete prion protein
uncertain. Three mutants isolated by virtue of their fluo-
rescence had either one or two residue changes when
compared to the parental sequence. Changes at residue 84
(mutant 17) and 47 (part of mutant M22) were outside of
the known prion structure [17] but in the case of residue
M17 changed the character of the residue from charged to
neutral. Of particular interest however is that one each of
the double mutations, E151V (mutant M22) and Y148H
(mutant M25) lie in the first alpha helix suggested to
interact with the N terminus [43,55] and mapped to be
the site of interaction of a major PrPc ligand, the laminin
receptor [75] (Figure 6). In addition the majority of
changes identified were charged residues (Figure 5).
Change of net charge, particularly among the familial
forms of amyloid disease proteins has been suggested to
have a major effect on protein solubility [58,74]. None of
the mutations associated with improved solubility coin-
cide directly with known prion polymorphisms although
interestingly residue 84 (mutant M17) is the point of sev-
eral octarepeat insertions associated with Gerstmann-
Sträussler-Scheinker Syndrome [76,77]. However,
although our data add direct experimental support to the
notion that prion protein folding is very susceptible to
minor changes of sequence, it does not directly address
the role of prion protein solubility in the pathogenicity of
prion disease.
Mutants M17, 22 and 25, selected by recovery of fluores- cence, were grown and PrPc-GFP fusion protein present in  the soluble (S) and insoluble (I) fractions of each induced cul- ture after detergent lysis were resolved by 10% SDS-PAGE  and probed with the prion monoclonal antibody 6H4 Figure 4
Mutants M17, 22 and 25, selected by recovery of fluores-
cence, were grown and PrPc-GFP fusion protein present in 
the soluble (S) and insoluble (I) fractions of each induced cul-
ture after detergent lysis were resolved by 10% SDS-PAGE 
and probed with the prion monoclonal antibody 6H4. Reac-
tion with mutant M22 has been largely lost due to degrada-
tion in the soluble phase and only residual insoluble material 
is detected.
Direct selection of Pc 
23–231-GFP mutants with increased fluo- rescence Figure 3
Direct selection of Pc 
23–231-GFP mutants with increased fluo-
rescence. Fluorescence of the three prion mutants (17, 22 
and 25) isolated by the procedures described. Each was 
grown overnight on agar plates and a heavy inoculum trans-
ferred to a sectored agar plate supplemented with IPTG to 
induce expression of the fusion protein. After three hours at 
37 degrees the plate was photographed under UV light.Virology Journal 2006, 3:59 http://www.virologyj.com/content/3/1/59
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Conclusion
Prion protein misfolding is thought to underlie its
involvement with the TSE diseases and its study, directly
or indirectly, may help determine the molecular mecha-
nisms involved. Use of GFP as a folding reporter has been
well described but its use as a probe of prion innate fold-
ing rather than cellular targeting has not been previously
reported. The GFP fluorescence assay we have described
may be useful for assessing a number of prion mutations
and the interaction of PrPc with its various reported lig-
ands [78].
Methods
E.coli strains
E.coli Top 10 (Invitrogen) was used throughout for clon-
ing. Plasmids were transformed into E.coli  BL21 DE3
(pLysS) (Novagen) for T7 driven protein production.
Plasmid construction
Mouse  Prnpa  allele (accession A23544) and enhanced
green fluorescence protein (accession AAC53663) were
used throughout. cDNA fragments encoding amino acids
23–231 and the N-terminal residues 23–156, 29–156,
76–156, 23–169 and 29–169 were amplified by the
polymerase chain reaction (PCR) to be flanked by restric-
tion sites for Bam H1 and first cloned into baculovirus
transfer vector pAcVSVGTMGFP [79] for expression in
insect cells [43]. Each construct was then used as a tem-
plate to amplify the sequence encoding the fusion of PrPc
and eGFP flanking the sequence with restriction sites
Nde1 and Xho1 at the 5' at the 3' ends respectively. Frag-
ments were digested with the same enzymes and cloned
into pET23a (Novagen) through the same sites to produce
PrPc-GFP gene fusions under the control of the T7 pro-
moter.
Expression libraries
A degenerate library of prion sequences was created by
error prone PCR [56] and cloned en masse into pET23a
upstream of, and in frame with, a sequence encoding
eGFP. Several library members were picked at random for
nucleotide sequencing to ensure errors had been intro-
duced. The library was maintained in E.coli BL21 pLysS in
an un-induced state and induced for fluorescence screen-
ing by replica plating to agar containing 2 mM IPTG. Col-
Location of the mutations selected by fluorescence recovery  in the three dimensional structure of the prion protein Figure 6
Location of the mutations selected by fluorescence recovery 
in the three dimensional structure of the prion protein. The 
unstructured amino terminus up to residue 90 is represented 
by the grey oval. The amino and carboxyl termini of the 
solved structure and the location of helix 1 are indicated.
Sequence alignment of mutants M17, 22 and 25 compared to the mouse wild type sequence Figure 5
Sequence alignment of mutants M17, 22 and 25 compared to the mouse wild type sequence. Only those areas showing changes 
are shown. Amino acid changes that cause a change of net charge are indicated by the asterisk below the aligned sequence.Virology Journal 2006, 3:59 http://www.virologyj.com/content/3/1/59
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onies were screened visually after a further 5 hours
incubation and positives re-streaked to ensure positivity
bred true. Once confirmed, uninduced colonies were re-
streaked from the master plate and DNA isolated for
sequencing.
Purification of inclusion bodies (IBs)
IBs were prepared by a modified differential solubility
regime [80]. Following inoculation of a single colony into
Luria broth cultures were induced with IPTG (0.2 mM) at
an OD600 of 0.5. Cultures were grown for a further 2
hours and bacteria harvested by centrifugation at 4500
rpm for 20 minutes at 4°C. The pellet was resuspended in
10 ml PBS and the IBs released by sonication on ice for 10
minutes, 1% triton X-100 (v/v) was added to complete
solublization and the IBs collected by centrifugation at
4500 rpm for 10 minutes. The pellet was washed repeat-
edly with 1% Triton X-100 until the purity of the IBs was
at least 90 % as judged by SDS-PAGE.
Protein refolding
IBs were denatured and reduced at 95°C for 5 minute in
4 M Urea and then clarified by ultracentrifugation. Refold-
ing was initiated by a single 7× dilution step into a buffer
containing 50 mM Tris.HCl pH8.5, 1 mM KCl, 2 mM
MgCl2. Recovery of fluorescence over time was monitored
by periodic fluorescence measurement at 510 nm in a
Genios microplate reader (Tecan). Assays were done in
duplicate and the average fluorescent units plotted against
time. To assess the role of metal ions in refolding buffers
were depleted for ions my mixing with chelex-100 (Bio-
Rad) as described [25] and filtering prior to constitution
of the assay. Ranging studies showed that the addition of
copper above 10 micromolar was found to be generally
inhibitory (i.e. inhibited the refolding of GFP only).
Purification of RNA
Total RNA for inclusion in the refolding assay was pre-
pared from SNB cells as described for RNA that stimulates
PrPc-PrPSc conversion [51]. Briefly, cells were washed with
PBS and resuspended in 1 ml of Trizol (Invitrogen). The
lysate was extracted with chloroform and the RNA recov-
ered by precipitation with isopropanol. The pellet was
washed with 75% ethanol, air dried, resuspended in RNA-
ase free water and quantitated by A260.
Protease K digestion
RNA stimulated partial protection of PrPc was assessed by
digestion of the reaction products after refolding with pro-
tease K as described [52].
Western blotting
Protein samples to be analyzed were separated on pre-cast
10% Tris-HCl SDS-polyacrylamide gels (Bio-Rad) and
transferred onto Immobilon-P transfer membrane (Milli-
pore). Western blotting was performed as described (Bur-
nette, 1981) except that sensitivity was increased through
the use of a biotin conjugated secondary antibody fol-
lowed by extravidin-peroxidase (Sigma). The membrane
was finally developed with BM Chemiluminescence
(Roche). The primary antibodies used were prion mono-
clonal antibodies 6H4 (Prionics) and anti-GFP (Clon-
tech).
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